Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Application (Early Detection, Diagnostics), By Indication (Oncology, Neurology), By Test Location, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 2 Business Days
Personalized Medicine Biomarkers Market Growth & Trends
The global personalized medicine biomarkers market size is expected to reach USD 43.07 billion by 2030, expanding at a CAGR of 15.51% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.
Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.
Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.
Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.
Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.
Personalized Medicine Biomarkers Market Report Highlights
Personalized Medicine Biomarkers Market Growth & Trends
The global personalized medicine biomarkers market size is expected to reach USD 43.07 billion by 2030, expanding at a CAGR of 15.51% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.
Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.
Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.
Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.
Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.
Personalized Medicine Biomarkers Market Report Highlights
- Early detection/screening segment is expected to grow at the fastest CAGR owing to the need to provide early treatment to patients
- Oncology segment held the largest market share in 2021 owing to the rising prevalence of cancer and the wide availability of FDA-approved personalized biomarkers tests for cancer
- North America held the largest market share attributable to the presence of improved healthcare infrastructure, rising prevalence of target diseases, and increasing government funding for innovation in biomarkers
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 PERSONALIZED MEDICINE BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1 Personalized Medicine Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (IVD) Market
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.4 Market Driver Analysis
3.4.1 Increasing prevalence of chronic diseases
3.4.2 Rising awareness and importance of predicting prognosis and selection of dose
3.4.3 Need to provide early diagnosis and treatment
3.5 Market Restraint Analysis
3.5.1 Regulatory & reimbursement hurdles
3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.7 Porter’s Five Forces Analysis
CHAPTER 4 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY CIRCULATING BIOMARKERS, 2018 - 2030 (USD MILLION)
4.1 Personalized Medicine Biomarkers Market: Application Movement Analysis
4.1.1 Early Detection/Screening
4.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.2 Diagnosis
4.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.3 Treatment Selection
4.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.4 Monitoring
4.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 5 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY INDICATION, 2018 - 2030 (USD MILLION)
5.1 Personalized Medicine Biomarkers Market: Indication Movement Analysis
5.1.1 Oncology
5.1.1.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2 Neurology
5.1.2.1 Neurology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3 Diabetes
5.1.3.1 Diabetes Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4 Autoimmune Diseases
5.1.4.1 Autoimmune Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5 Cardiology
5.1.5.1 Cardiology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.6 Others
5.1.6.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 6 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Personalized Medicine Biomarkers Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3 Europe
6.3.1 Europe Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.4 France
6.3.4.1 France Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.5 Italy
6.3.5.1 Italy Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.6 Spain
6.3.6.1 Spain Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.3 China
6.4.3.1 China Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.4 India
6.4.4.1 India Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.4 Australia
6.4.4.1 Australia Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.5 South Korea
6.4.5.1 South Korea Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.3 Argentina
6.5.3.1 Argentina Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6 MEA
6.6.1 MEA Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
CHAPTER 7 PERSONALIZED MEDICINE BIOMARKERS MARKET: COMPETITIVE ANALYSIS
7.1 Recent developments and impact analysis, by key market participants
7.1.1 Ansoff Matrix
7.1.2 Major Deals And Strategic Alliances Analysis
7.1.2.1 Market Expansion
7.1.2.2 Product launch
7.1.2.3 Acquisition
7.1.2.4 Partnerships and Collaborations
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.3 Vendor Landscape
7.3.1 List Of Key Distributors And Channel Partners
7.3.2 Key Customers
7.3.3 Key Company Market Share Analysis, 2021
7.4 Public Companies
7.4.1 Company Market Position Analysis
7.4.2 Heat Map Analysis
7.4.3 Regional Network Map
7.4.4 Competitive Dashboard Analysis
7.4.4.1 Market Differentiators
7.5 Private Companies
7.5.1 List Of Key Emerging Companies
7.5.2 Heat Map Analysis
7.5.3 Regional Network Map
CHAPTER 8 COMPANY PROFILES
8.1 Laboratory Corporation of America Holding
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Quest Diagnostics Incorporated
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Agilent Technologies, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.2 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Genome Medical, Inc.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Thermo Fisher Scientific, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Coriell Life Sciences.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.2 Product Benchmarking
8.9.4 Strategic Initiatives
8.7 NeoGenomics Laboratories
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 FOUNDATION MEDICINE, INC.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.9 Illumina, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Guardant Health
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Exact Sciences Corporation.
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 PERSONALIZED MEDICINE BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1 Personalized Medicine Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (IVD) Market
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.4 Market Driver Analysis
3.4.1 Increasing prevalence of chronic diseases
3.4.2 Rising awareness and importance of predicting prognosis and selection of dose
3.4.3 Need to provide early diagnosis and treatment
3.5 Market Restraint Analysis
3.5.1 Regulatory & reimbursement hurdles
3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.7 Porter’s Five Forces Analysis
CHAPTER 4 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY CIRCULATING BIOMARKERS, 2018 - 2030 (USD MILLION)
4.1 Personalized Medicine Biomarkers Market: Application Movement Analysis
4.1.1 Early Detection/Screening
4.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.2 Diagnosis
4.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.3 Treatment Selection
4.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.1.4 Monitoring
4.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 5 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY INDICATION, 2018 - 2030 (USD MILLION)
5.1 Personalized Medicine Biomarkers Market: Indication Movement Analysis
5.1.1 Oncology
5.1.1.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2 Neurology
5.1.2.1 Neurology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3 Diabetes
5.1.3.1 Diabetes Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.4 Autoimmune Diseases
5.1.4.1 Autoimmune Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.5 Cardiology
5.1.5.1 Cardiology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.6 Others
5.1.6.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 6 PERSONALIZED MEDICINE BIOMARKERS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Personalized Medicine Biomarkers Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3 Europe
6.3.1 Europe Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.4 France
6.3.4.1 France Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.5 Italy
6.3.5.1 Italy Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.3.6 Spain
6.3.6.1 Spain Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.3 China
6.4.3.1 China Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.4 India
6.4.4.1 India Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.4 Australia
6.4.4.1 Australia Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.4.5 South Korea
6.4.5.1 South Korea Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.5.3 Argentina
6.5.3.1 Argentina Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6 MEA
6.6.1 MEA Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Personalized Medicine Biomarkers Market, 2018 - 2030 (USD Million)
CHAPTER 7 PERSONALIZED MEDICINE BIOMARKERS MARKET: COMPETITIVE ANALYSIS
7.1 Recent developments and impact analysis, by key market participants
7.1.1 Ansoff Matrix
7.1.2 Major Deals And Strategic Alliances Analysis
7.1.2.1 Market Expansion
7.1.2.2 Product launch
7.1.2.3 Acquisition
7.1.2.4 Partnerships and Collaborations
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.3 Vendor Landscape
7.3.1 List Of Key Distributors And Channel Partners
7.3.2 Key Customers
7.3.3 Key Company Market Share Analysis, 2021
7.4 Public Companies
7.4.1 Company Market Position Analysis
7.4.2 Heat Map Analysis
7.4.3 Regional Network Map
7.4.4 Competitive Dashboard Analysis
7.4.4.1 Market Differentiators
7.5 Private Companies
7.5.1 List Of Key Emerging Companies
7.5.2 Heat Map Analysis
7.5.3 Regional Network Map
CHAPTER 8 COMPANY PROFILES
8.1 Laboratory Corporation of America Holding
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Quest Diagnostics Incorporated
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Agilent Technologies, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.2 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Genome Medical, Inc.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Thermo Fisher Scientific, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Coriell Life Sciences.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.2 Product Benchmarking
8.9.4 Strategic Initiatives
8.7 NeoGenomics Laboratories
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 FOUNDATION MEDICINE, INC.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.9 Illumina, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Guardant Health
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Exact Sciences Corporation.
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global personalized medicine biomarkers market, by region, 2018 - 2030 (USD Million)
TABLE 5 Global personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 6 Global personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 7 North America personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 8 North America personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 9 North America personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 10 U.S. personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 11 U.S. personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 12 Canada personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 13 Canada personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 14 Europe personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 15 Europe personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 16 Europe personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 17 U.K. personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 18 U.K. personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 19 Germany personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 20 Germany personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 21 Spain personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 22 Spain personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 23 France personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 24 France personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 25 Italy personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 26 Italy personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 27 Asia Pacific personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 28 Asia Pacific personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 29 Asia Pacific personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 30 Japan personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 31 Japan personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 32 China personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 33 China personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 34 India personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 35 India personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 36 Australia personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 37 Australia personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 38 South Korea personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 39 South Korea personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 40 South Korea personalized medicine biomarkers market, by product application, 2018 - 2030 (USD Million)
TABLE 41 Latin America personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 42 Latin America personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 43 Latin America personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 44 Brazil personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 45 Brazil personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 46 Mexico personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 47 Mexico personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 48 Argentina personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 49 Argentina personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 50 MEA personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 51 MEA personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 52 MEA personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 53 South Africa personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 54 South Africa personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 55 Saudi Arabia personalized medicine biomarkers market, by application, 2018 - 2030, (USD Million)
TABLE 56 Saudi Arabia personalized medicine biomarkers market, by indication, 2018 - 2030, (USD Million)
TABLE 57 UAE personalized medicine biomarkers market, by application, 2018 - 2030, (USD Million)
TABLE 58 UAE personalized medicine biomarkers market, by indication, 2018 - 2030, (USD Million)
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global personalized medicine biomarkers market, by region, 2018 - 2030 (USD Million)
TABLE 5 Global personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 6 Global personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 7 North America personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 8 North America personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 9 North America personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 10 U.S. personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 11 U.S. personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 12 Canada personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 13 Canada personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 14 Europe personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 15 Europe personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 16 Europe personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 17 U.K. personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 18 U.K. personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 19 Germany personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 20 Germany personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 21 Spain personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 22 Spain personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 23 France personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 24 France personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 25 Italy personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 26 Italy personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 27 Asia Pacific personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 28 Asia Pacific personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 29 Asia Pacific personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 30 Japan personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 31 Japan personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 32 China personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 33 China personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 34 India personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 35 India personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 36 Australia personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 37 Australia personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 38 South Korea personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 39 South Korea personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 40 South Korea personalized medicine biomarkers market, by product application, 2018 - 2030 (USD Million)
TABLE 41 Latin America personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 42 Latin America personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 43 Latin America personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 44 Brazil personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 45 Brazil personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 46 Mexico personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 47 Mexico personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 48 Argentina personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 49 Argentina personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 50 MEA personalized medicine biomarkers market, by country, 2018 - 2030 (USD Million)
TABLE 51 MEA personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 52 MEA personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 53 South Africa personalized medicine biomarkers market, by application, 2018 - 2030 (USD Million)
TABLE 54 South Africa personalized medicine biomarkers market, by indication, 2018 - 2030 (USD Million)
TABLE 55 Saudi Arabia personalized medicine biomarkers market, by application, 2018 - 2030, (USD Million)
TABLE 56 Saudi Arabia personalized medicine biomarkers market, by indication, 2018 - 2030, (USD Million)
TABLE 57 UAE personalized medicine biomarkers market, by application, 2018 - 2030, (USD Million)
TABLE 58 UAE personalized medicine biomarkers market, by indication, 2018 - 2030, (USD Million)
LIST OF FIGURES
FIG. 1 Personalized medicine biomarkers market segmentation
FIG. 2 Market research process
FIG. 3 Data triangulation techniques
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Personalized medicine biomarkers market snapshot
FIG. 10 Penetration and growth prospect mapping for application, 2021 (USD Million)
FIG. 11 Market Dynamics
FIG. 12 Personalized medicine biomarkers market driver impact
FIG. 13 Personalized medicine biomarkers market restraint impact
FIG. 14 Porter’s five forces analysis
FIG. 15 Personalized medicine biomarkers market: Application outlook and key takeaways
FIG. 16 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 17 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 18 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 19 Monitoring circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 20 Personalized medicine biomarkers market: Indication outlook and key takeaways
FIG. 21 Personalized medicine biomarkers market: Indication movement analysis
FIG. 22 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 23 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 24 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 25 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 26 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 28 Personalized Medicine Biomarkers Market: Regional outlook and key takeaways
FIG. 29 Breast cancer liquid biopsy: Regional movement analysis
FIG. 30 North America
FIG. 31 North America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 32 U.S.
FIG. 33 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 34 Canada
FIG. 35 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 36 Europe
FIG. 37 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 38 U.K.
FIG. 39 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 40 Germany
FIG. 41 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 42 France
FIG. 43 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 44 Spain
FIG. 45 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 46 Italy
FIG. 47 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 48 Asia Pacific
FIG. 49 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 50 Japan
FIG. 51 Japan market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 52 China
FIG. 53 China. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 54 India
FIG. 55 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 56 Australia
FIG. 57 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 58 South Korea
FIG. 59 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 Latin America
FIG. 61 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Brazil
FIG. 63 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Mexico
FIG. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 Argentina
FIG. 67 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 MEA
FIG. 69 MEA market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 South Africa
FIG. 71 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Saudi Arabia
FIG. 73 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 UAE
FIG. 75 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 Ansoff Matrix
FIG. 77 Strategy mapping
FIG. 78 Company market share analysis, 2021
FIG. 79 Heat Map Analysis
FIG. 80 Market differentiators
FIG. 81 Heat Map Analysis
FIG. 82 Regional Network Map
FIG. 1 Personalized medicine biomarkers market segmentation
FIG. 2 Market research process
FIG. 3 Data triangulation techniques
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Personalized medicine biomarkers market snapshot
FIG. 10 Penetration and growth prospect mapping for application, 2021 (USD Million)
FIG. 11 Market Dynamics
FIG. 12 Personalized medicine biomarkers market driver impact
FIG. 13 Personalized medicine biomarkers market restraint impact
FIG. 14 Porter’s five forces analysis
FIG. 15 Personalized medicine biomarkers market: Application outlook and key takeaways
FIG. 16 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 17 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 18 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 19 Monitoring circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 20 Personalized medicine biomarkers market: Indication outlook and key takeaways
FIG. 21 Personalized medicine biomarkers market: Indication movement analysis
FIG. 22 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 23 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 24 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 25 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 26 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 28 Personalized Medicine Biomarkers Market: Regional outlook and key takeaways
FIG. 29 Breast cancer liquid biopsy: Regional movement analysis
FIG. 30 North America
FIG. 31 North America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 32 U.S.
FIG. 33 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 34 Canada
FIG. 35 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 36 Europe
FIG. 37 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 38 U.K.
FIG. 39 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 40 Germany
FIG. 41 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 42 France
FIG. 43 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 44 Spain
FIG. 45 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 46 Italy
FIG. 47 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 48 Asia Pacific
FIG. 49 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 50 Japan
FIG. 51 Japan market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 52 China
FIG. 53 China. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 54 India
FIG. 55 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 56 Australia
FIG. 57 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 58 South Korea
FIG. 59 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 Latin America
FIG. 61 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Brazil
FIG. 63 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Mexico
FIG. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 Argentina
FIG. 67 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 MEA
FIG. 69 MEA market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 South Africa
FIG. 71 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Saudi Arabia
FIG. 73 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 UAE
FIG. 75 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 Ansoff Matrix
FIG. 77 Strategy mapping
FIG. 78 Company market share analysis, 2021
FIG. 79 Heat Map Analysis
FIG. 80 Market differentiators
FIG. 81 Heat Map Analysis
FIG. 82 Regional Network Map
